Marimed Inc. (OTC: MRMD), an SEC filer in Medicinal Chemicals & Botanical Products, closed at $0.09, -3.2%, on 2026-08-28, with a market cap of $36M as of 2026-08-27, a net margin of -9.1% and 3-year sales growth of 5.1%. Institutional ownership, earnings history and filed financials are on the tabs below.
Returns use ADJUSTED closes (splits + dividends).
Volume as VALUE TRADED — close × volume, in USD.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | MRMD | SPY | Δ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 · ytd | −7.4% | −2.3% | −18.8% | +29.0% | −12.4% | −10.3% | −10.0% | +38.1% | — | — | — | — | −7.4% | +13.4% | −20.9pp |
| 2025 | −3.3% | +1.8% | −17.5% | +13.8% | −21.5% | −17.9% | +42.0% | +57.1% | −3.2% | −18.1% | −26.6% | +4.9% | −18.8% | +17.7% | −36.5pp |
| 2024 | +21.9% | −18.5% | −3.3% | +23.1% | −33.8% | −15.8% | −1.2% | +3.7% | −7.3% | −7.0% | −8.1% | −21.2% | −57.9% | +24.9% | −82.7pp |
| 2023 | +15.0% | +5.2% | −8.8% | −2.5% | +5.7% | +1.2% | −7.2% | +11.6% | +2.7% | −25.0% | −9.5% | −7.2% | −22.8% | +26.2% | −49.0pp |
| 2022 | −9.8% | +0.0% | −6.4% | −12.3% | −4.7% | −23.0% | +54.3% | −15.9% | −29.0% | +27.0% | −3.4% | −33.0% | −58.8% | −18.2% | −40.7pp |
| 2021 | +40.4% | +11.4% | +6.1% | −5.1% | +48.5% | −14.2% | −9.2% | +11.5% | −5.8% | −17.8% | −5.4% | +23.6% | +84.0% | +28.7% | +55.3pp |
| 2020 | −31.5% | −40.9% | −29.2% | −13.0% | +16.9% | −12.7% | −10.9% | +29.5% | −11.2% | −10.1% | +261.4% | −10.1% | −23.9% | +18.3% | −42.3pp |
| 2019 | +24.3% | −3.5% | −10.3% | −5.1% | −15.1% | −28.4% | −27.2% | −11.6% | −23.1% | +0.0% | −27.0% | −15.4% | −81.0% | +31.2% | −112.2pp |
| 2018 | +88.4% | −11.5% | −1.7% | +5.3% | +42.9% | +35.9% | −10.0% | +29.5% | +39.4% | +18.9% | −6.5% | −22.1% | +371.0% | −4.6% | +375.6pp |
| 2017 | −2.2% | +47.9% | −17.6% | −5.4% | +200.2% | −20.8% | +2.4% | −1.8% | −27.5% | −25.9% | +105.6% | −1.3% | +193.6% | +21.7% | +171.9pp |
Month-end over prior month-end; a blank cell is no return.
Basis. Both columns share one basis, so Δ is like-for-like.
End-of-day closes; a “ytd” or “part” year is not a full year.
| Month | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Years ⓘ | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Positive ⓘ | 50% | 50% | 21% | 43% | 43% | 29% | 21% | 57% | 36% | 29% | 21% | 29% |
| Median | +7.5% | +0.9% | −9.4% | −3.8% | −4.3% | −12.6% | −7.2% | +4.6% | −4.5% | −4.8% | −6.0% | −4.2% |
| Best | +88.4% | +109.3% | +33.3% | +43.0% | +200.2% | +35.9% | +54.3% | +57.1% | +39.4% | +38.5% | +261.4% | +23.6% |
| Worst | −31.5% | −40.9% | −30.1% | −13.3% | −33.8% | −28.4% | −27.2% | −35.0% | −29.0% | −28.9% | −27.0% | −44.4% |
| vs SPY ⓘ | +6.1pp | +3.0pp | −11.4pp | −3.8pp | −5.6pp | −14.5pp | −10.3pp | +1.5pp | −5.0pp | −6.9pp | −8.6pp | −7.2pp |
168 monthly observations · 2012–2026 · benchmark SPY
